Intensive Glycemic Control May Cut CV Autonomic Neuropathy Risk
Greatest CAN prevention effect seen among type 2 diabetes patients without cardiovascular disease history.
Greatest CAN prevention effect seen among type 2 diabetes patients without cardiovascular disease history.
Five cases of euDKA identified in patients with type 2 diabetes using SGLT2 inhibitors who developed SARS-CoV-2 infection.
One-year increase in age at diabetes diagnosis linked to lower risk for all-cause mortality and macrovascular, microvascular disease.
Risk for severe COVID-19 similar among those with type 1 and type 2 diabetes
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m2 with no increase in AKI
More than one-third of T2DM patients without established cardiovascular disease had very high risk for CV events
Please login or register first to view this content.